Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 13/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502732 | 1.00 | UHRF1 (0.42) | UHRF1LPLLIPGIRAK4CA1 | |
| SCHEMBL27978516 | 0.82 | UHRF1 (0.34) | UHRF1IRAK4 | |
| SCHEMBL20099926 | 0.82 | HDAC3 (0.39) | UHRF1LPLLIPGIRAK4CA1 | |
| SCHEMBL18162730 | 0.82 | LIPG (0.56) | LPLLIPGIRAK4CA1CA2 | |
| SCHEMBL23496480 | 0.80 | LPL (0.41) | LPLLIPGIRAK4CA1CA2 | |
| SCHEMBL17053327 | 0.80 | LPL (0.41) | LPLLIPGIRAK4CA1CA2 | |
| SCHEMBL614168 | 0.80 | NOS3 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL394155 | 0.80 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12069605 | 0.80 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL613614 | 0.80 | LPL (0.47) | LPLLIPGIRAK4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124222-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4212523-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727938-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| WO-2009043884-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2008-06-12 | — | — | US | disclosed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | disclosed |
| CN-1688580-A | 2-Trifluoromethyl-6-aminopurine derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE3A | UHRF1 3764/4885LPL 212/4885LIPG 130/4885 |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | UHRF1 3764/4885LPL 212/4885LIPG 130/4885 |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | UHRF1 3040/4885LPL 2098/4885LIPG 4057/4885 |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | UHRF1 4292/4885LPL 4312/4885LIPG 1708/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | UHRF1 4532/4885LPL 2/4885LIPG 17/4885 |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | ROCK1, RHOC, ROCK2 | UHRF1 2239/4885LPL 4109/4885LIPG 2563/4885 |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | GRM2, GRM1, GRM3 | UHRF1 4030/4885LPL 4102/4885LIPG 4656/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | UHRF1 2127/4885LPL 1712/4885LIPG 1552/4885 |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | UHRF1 4292/4885LPL 4312/4885LIPG 1708/4885 |
| US-20260124222-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL6B | UHRF1 1118/4885LPL 2409/4885LIPG 2267/4885 |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | UHRF1 2939/4885LPL 4325/4885LIPG 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.